Skip to search formSkip to main contentSkip to account menu

BM 13505

Known as: BM 13.505, BM-13505 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

daltroban

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022.
1995
1995
Platelet-activating factor increases vascular resistance in rat hindquarters by thromboxane A2.
The effects of platelet-activating factor (PAF) on vascular resistance and capillary permeability were studied in the isolated… 
1993
1993
Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs.
The antithrombotic effects of the thromboxane (TX) A2-receptor antagonist and aspirin were determined using a photochemically… 
1993
1993
[Effects of KW-3635 on the diuretic action of furosemide in rats].
The effects of KW-3635 (sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl) ethylidene]-6,11-dihydrodibenz-[b,e]oxepine-2… 
1989
1989
Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats.
1988
1988
Protective effects of thromboxane receptor blockade in splanchnic artery occlusion shock.
Splanchnic artery occlusion (SAO) followed by release of the occlusive clamps produces circulatory shock characterized by an… 
1986
1986
Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.
The new specific thromboxane receptor antagonist, BM-13505, was infused intravenously (1 mg/kg bolus and 1 mg/kg hr continuous… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)